Literature DB >> 34378447

Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder.

Jacinta Saldaris1, Judith Weisenberg2, Elia Pestana-Knight3, Eric D Marsh4, Bernhard Suter5, Rajsekar Rajaraman6, Gena Heidary7, Heather E Olson8, Orrin Devinsky9, Dana Price9, Peter Jacoby1, Helen Leonard1,10, Tim A Benke11, Scott Demarest11, Jenny Downs1,12.   

Abstract

CDKL5 deficiency disorder (CDD) results in early-onset seizures and severe developmental impairments. A CDD clinical severity assessment (CCSA) was previously developed with clinician and parent-report items to capture information on a range of domains. Consistent with US Food and Drug Administration (FDA) guidelines, content validation is the first step in evaluating the psychometric properties of an outcome measure. The aim of this study was to validate the content of the clinician-reported items in the CCSA (CCSA-Clinician). Eight neurologists leading the USA CDD Center of Excellence clinics were interviewed using the "think aloud" technique to critique 26 clinician-reported items. Common themes were aggregated, and a literature search of related assessments informed item modifications. The clinicians then participated in 2 consensus meetings to review themes and finalize the items. A consensus was achieved for the content of the CCSA-Clinician. Eight of the original items were omitted, 11 items were added, and the remaining 18 items were revised. The final 29 items were classified into 2 domains: functioning and neurologic impairments. This study enabled refinement of the CCSA-Clinician and provided evidence for its content validity. This preliminary validation is essential before field testing and further validation, in order to advance the instrument toward clinical trial readiness.

Entities:  

Keywords:  CDKL5 deficiency disorder; clinical severity; content validity; outcome measure; think aloud

Mesh:

Year:  2021        PMID: 34378447      PMCID: PMC8458223          DOI: 10.1177/08830738211019576

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  29 in total

Review 1.  Alertness in individuals with profound intellectual and multiple disabilities: a literature review.

Authors:  V S Munde; C Vlaskamp; A J J M Ruijssenaars; H Nakken
Journal:  Res Dev Disabil       Date:  2008-08-27

2.  Assessment of a Clinical Trial Metric for Rett Syndrome: Critical Analysis of the Rett Syndrome Behavioural Questionnaire.

Authors:  Wei Hou; Usree Bhattacharya; Wisnu A Pradana; Daniel C Tarquinio
Journal:  Pediatr Neurol       Date:  2020-02-04       Impact factor: 3.372

Review 3.  Consensus development methods: a review of best practice in creating clinical guidelines.

Authors:  N Black; M Murphy; D Lamping; M McKee; C Sanderson; J Askham; T Marteau
Journal:  J Health Serv Res Policy       Date:  1999-10

Review 4.  Severity Assessment in CDKL5 Deficiency Disorder.

Authors:  Scott Demarest; Elia M Pestana-Knight; Heather E Olson; Jenny Downs; Eric D Marsh; Walter E Kaufmann; Carol-Anne Partridge; Helen Leonard; Femida Gwadry-Sridhar; Katheryn Elibri Frame; J Helen Cross; Richard F M Chin; Sumit Parikh; Axel Panzer; Judith Weisenberg; Karen Utley; Amanda Jaksha; Sam Amin; Omar Khwaja; Orrin Devinsky; Jeffery L Neul; Alan K Percy; Tim A Benke
Journal:  Pediatr Neurol       Date:  2019-03-27       Impact factor: 3.372

5.  Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder.

Authors:  Stephanie Fehr; Kingsley Wong; Richard Chin; Simon Williams; Nick de Klerk; David Forbes; Rahul Krishnaraj; John Christodoulou; Jenny Downs; Helen Leonard
Journal:  Neurology       Date:  2016-10-21       Impact factor: 9.910

6.  Movement Disorder-Childhood Rating Scale: A Sensitive Tool to Evaluate Movement Disorders.

Authors:  Roberta Battini; Ilaria Olivieri; Roberta Di Pietro; Manuela Casarano; Giuseppina Sgandurra; Domenico M Romeo; Giovanni Cioni
Journal:  Pediatr Neurol       Date:  2015-03-27       Impact factor: 3.372

7.  CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.

Authors:  Scott T Demarest; Heather E Olson; Angela Moss; Elia Pestana-Knight; Xiaoming Zhang; Sumit Parikh; Lindsay C Swanson; Katherine D Riley; Grace A Bazin; Katie Angione; Lisa-Marie Niestroj; Dennis Lal; Elizabeth Juarez-Colunga; Tim A Benke
Journal:  Epilepsia       Date:  2019-07-16       Impact factor: 5.864

8.  Developing the Pediatric Refractory Epilepsy Questionnaire: a pilot study.

Authors:  Vaishnavi Purusothaman; Robin C C Ryther; Mary Bertrand; Lisa A Harker; Donna B Jeffe; Michael Wallendorf; Matthew D Smyth; David D Limbrick
Journal:  Epilepsy Behav       Date:  2014-06-23       Impact factor: 2.937

9.  Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome.

Authors:  J L Neul; P Fang; J Barrish; J Lane; E B Caeg; E O Smith; H Zoghbi; A Percy; D G Glaze
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

10.  CDKL5 Deficiency Disorder-A Complex Epileptic Encephalopathy.

Authors:  Martyna Jakimiec; Justyna Paprocka; Robert Śmigiel
Journal:  Brain Sci       Date:  2020-02-17
View more
  2 in total

1.  International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.

Authors:  Sam Amin; Marie Monaghan; Angel Aledo-Serrano; Nadia Bahi-Buisson; Richard F Chin; Angus J Clarke; J Helen Cross; Scott Demarest; Orrin Devinsky; Jenny Downs; Elia M Pestana Knight; Heather Olson; Carol-Anne Partridge; Graham Stuart; Marina Trivisano; Sameer Zuberi; Tim A Benke
Journal:  Front Neurol       Date:  2022-06-20       Impact factor: 4.086

Review 2.  Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies.

Authors:  Elizabeth E Palmer; Katherine Howell; Ingrid E Scheffer
Journal:  Neurotherapeutics       Date:  2021-10-27       Impact factor: 6.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.